These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2503657)

  • 1. [Effect of the drug Humex on the development of experimental motion sickness].
    Bodo G; Elkan K; Bentse G
    Kosm Biol Aviakosm Med; 1989; 23(3):84. PubMed ID: 2503657
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of a combination of chlorcyclizine hydrochloride and cinnarizine on the linear acceleration test.
    Oosterveld WJ; Zelig S
    Acta Physiol Pharmacol Neerl; 1965; 13(3):348-54. PubMed ID: 4379950
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevention of motion sickness with selegilinum hydrochloricum.
    Bodó G; Elkán K; Bencze G
    Ther Hung; 1989; 37(2):103-6. PubMed ID: 2511643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled trial of L-deprenyl in atypical depression.
    McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM
    Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy of betaserk in experimental motor disease].
    Mantsev EI; Sigaleva EE
    Vestn Otorinolaringol; 2005; (6):49-52. PubMed ID: 16353011
    [No Abstract]   [Full Text] [Related]  

  • 6. [Model of motion sickness in white mice experiments].
    Zhabko EP; Lukomskaia NIa
    Aviakosm Ekolog Med; 1997; 31(6):66-8. PubMed ID: 9483286
    [No Abstract]   [Full Text] [Related]  

  • 7. Pergolide and selegiline for Parkinson's disease.
    Med Lett Drugs Ther; 1989 Sep; 31(800):81-3. PubMed ID: 2505028
    [No Abstract]   [Full Text] [Related]  

  • 8. [Requirement of an "ideal" drug for prevention of space motion sickness].
    Karkishchenko NN
    Kosm Biol Aviakosm Med; 1989; 23(6):33-6. PubMed ID: 2516579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of extra-puerperal galactorrhea with the MAO-B inhibitor selegiline].
    Sas M; Godó G; Koleszár G
    Orv Hetil; 1986 Jun; 127(25):1507-8, 1511. PubMed ID: 3088511
    [No Abstract]   [Full Text] [Related]  

  • 10. [The effect of vestibuloprotectors on the cyclic nucleotide system in experimental motion sickness].
    Leshchiniuk II; Konovalova EO; Kvitchataia AI; Shamraĭ VG; Bobkov IuG
    Patol Fiziol Eksp Ter; 1989; (1):26-8. PubMed ID: 2785671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The adequacy of a new method for assessing the vestibular protective effect of biologically active substances].
    Karkishchenko NN; Dimitriadi NA
    Farmakol Toksikol; 1991; 54(5):14-6. PubMed ID: 1800137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug effectiveness on experimental optokinetic and vestibular motion sickness.
    Brandt T; Dichgans J; Wagner W
    Aerosp Med; 1974 Nov; 45(11):1291-7. PubMed ID: 4611183
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of a new antinauseant drug for the prevention of motion sickness.
    Graybiel A; Knepton J
    Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
    Tariska I; Gallai M
    Orv Hetil; 1983 Sep; 124(38):2309-14. PubMed ID: 6415577
    [No Abstract]   [Full Text] [Related]  

  • 15. The laboratory assessment of anti-motion sickness and anti-vertigo drugs.
    Barber HO; Basser W; Johnson WH; Takahashi P
    Can Med Assoc J; 1967 Dec; 97(24):1460-5. PubMed ID: 4863013
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neurochemical mechanisms of the development of motion sickness].
    Iasnetsov VV; Shashkov VS
    Vestn Ross Akad Med Nauk; 1992; (7):16-21. PubMed ID: 1281702
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of sodium bicarbonate as a means of treating and preventing motion sickness].
    Barnatskiĭ VN; Brianov II; Volosevich RM; Komarova DP; Kuznetsov AG
    Kosm Biol Med; 1972; 6(6):70-5. PubMed ID: 4543441
    [No Abstract]   [Full Text] [Related]  

  • 18. Current controversies in the use of selegiline hydrochloride.
    Lees AJ
    J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 20. Some effects of l-hyoscine hydrobromide on post-rotatory sensation and nystagmus in man.
    Benson AJ; Brand JJ
    Q J Exp Physiol Cogn Med Sci; 1968 Jul; 53(3):296-311. PubMed ID: 5303051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.